25M, Aggressive Diffuse NW5 – 5 Months Minoxidil + 3 Months Oral Finasteride + RU58841 | Progress or Not?
    5/22/2026

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Tretinoin →

    the gold standard retinoid in dermatology that's also helpful for hair regrowth alongside Minoxidil

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💧 Minoxidil (topical) 5% 5 months
    💧 Tretinoin (topical) 5 months
    💊 Finasteride (oral) 1mg 3 months
    💧 RU58841 (topical) 20 mg
    💧 Ketoconazole (topical) 2% 4 per week
    Dermastamp 1mm once every 10 days
    the tone is 😞 negative with slow progress results.

    Other terms

    A 25-year-old with aggressive diffuse NW5 hair loss is using Minoxidil, oral Finasteride, RU58841, Ketoconazole, and dermastamping, experiencing slow progress and mental health struggles. Despite some visible regrowth, the user feels discouraged due to ongoing hair loss and is seeking reassurance and advice.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Treatments for Androgenetic Alopecia and Alopecia Areata

      research Treatments for Androgenetic Alopecia and Alopecia Areata

      72 citations , January 2001 in “Drugs”
      This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.
      Compounding as a Current Therapeutic Option in Dermatology

      research Compounding as a Current Therapeutic Option in Dermatology

      1 citations , October 2013 in “Actas Dermo-Sifiliográficas”
      This review discusses the current role and challenges of compounding in dermatology without presenting new research results; the authors suggest its resurgence in practice despite pharmaceutical alternatives.
      Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment

      research Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment

      August 2025 in “Drug Design Development and Therapy”
      This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.